14 April 2023
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company has received notification from Vulpes Investment Management Pte Ltd ("Vulpes") that on 12 and 13 April 2023 it purchased, respectively, 100,000 and 100,000 ordinary shares of 1p in the capital of the Company ("Ordinary Shares") at a price of 4p per Ordinary Share (the "Purchase"). Following the Purchase, Vulpes has a total direct and indirect interest in 67,789,772 Ordinary Shares, equivalent to 22.97% of Proteome Sciences' total issued share capital.
By virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 67,789,772 Ordinary Shares of the Company representing 22.97% of the issued share capital of the Company.
The below notification is made in accordance with the requirements of the Market Abuse (amendment) (EU Exit) Regulations 2019/310.
| 1. | Details of the person discharging managerial responsibilities/person closely associated | |||||||
| a) | Name: | Martin Diggle | ||||||
|
| Reason for the notification | |||||||
| a) | Position/status: | Non-Executive Director | ||||||
| b) | Initial notification/Amendment: | Initial Notification | ||||||
|
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||
| a) | Name: | Proteome Sciences Plc | ||||||
| b) | LEI: | 213800Q62ICXANKU2986 | ||||||
|
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||
| a) | Description of the financial instrument, type of instrument: Identification code: | Ordinary Shares of 1p nominal value GB0003104196 | ||||||
| b) | Nature of the transaction: | Purchase of Ordinary Shares | ||||||
| c) | Price(s) and volume(s): |
| ||||||
| d) | Aggregated information: · Aggregated volume: · Price: | Single transaction as in 4 c) above
| ||||||
| e) | Date of the transaction: | 12 and 13 April 2023 | ||||||
| f) | Place of the transaction: | London Stock Exchange, AIM (XLON) | ||||||
For further information please contact:
|
Proteome Sciences plc | ||
| Dr. Mariola Soehngen, Chief Executive Officer Dr. Ian Pike, Chief Scientific Officer | Tel: +44 (0)20 7043 2116 |
|
| Richard Dennis, Chief Commercial Officer Abdelghani Omari, Chief Financial Officer |
|
|
|
|
|
|
| Allenby Capital Limited (Nominated Adviser & Broker) |
| |
| John Depasquale / Jeremy Porter
| Tel: +44 (0) 20 3328 5656 |
|
|
| ||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.